PetVivo Holdings, Inc. announced it has received an initial regulatory assessment from a Contract Research Organization outlining pathways to regulatory approval of various indications for its proprietary Biomatrix Particulate Technology. The regulatory assessment will assist the Company in better understanding the regulatory pathway to approval of one or more human products such as dermal fillers, tendon and ligament repair, intraarticular injectable devices, urinary incontinence bulking agents and dental -- soft tissue augmentation biomaterials. The Company's first product that implemented the Biomatrix Particulate Technology, SPRYNG(TM) with OsteoCushion(TM) Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; SPRYNG microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis.

The Company's management team in cooperation with its human advisory task force anticipates regulatory plans to be completed for new human products implementing the Biomatrix Particulate Technology in the first part of calendar year 2024. The products for human use will be manufactured by PetVivo in its manufacturing facility in Edina, Minnesota, which is anticipated to be opened in the fourth quarter of 2023.